Phase
Condition
Epilepsy
Precancerous Condition
Neurofibromatosis
Treatment
Sirolimus
Placebo
Clinical Study ID
Ages 1-6 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
0-6 months of age at the time of enrollment (subject must be <7 months ofchronological age at time of randomization and treatment initiation). Corrected agemust be at least 39 weeks (calculated by subtracting the number of weeks born before 40 weeks gestation from the chronological age).
Has a confirmed diagnosis of TSC based on established clinical or genetic criteria
Exclusion
Exclusion Criteria:
Prior history of seizures (clinical or electrographic) at the time of enrollment oridentified on baseline EEG.
Has been treated in the past or is currently being treated at the time of enrollmentwith conventional anticonvulsant medications (AEDs), systemic (oral) mTOR inhibitors (such as rapamycin, sirolimus, or everolimus), ketogenic-related special diet, oranother anti-seizure therapeutic agent, device, or procedure.
Has taken any other investigational drug as part of another research study, within 30 days prior to the baseline screening visit.
Has a significant illness or active infection at the time of the baseline screeningvisit
Has a history of significant prematurity, defined as gestational age <30 weeks atthe time of delivery, or other significant medical complications at birth or duringthe neonatal period that other than TSC would convey additional risk of seizures orneurodevelopmental delay (i.e. HIE, severe neonatal infection, major surgery,prolonged ventilatory or other life-saving supportive care or procedures).
Abnormal laboratory values at baseline (i.e., renal function, liver function, orbone marrow production) that are in the opinion of the investigator clinicallysignificant and may jeopardize the safety of the study subject.
Prior, planned or anticipated neurosurgery within 3 months of the baseline visit
Has a TSC-associated condition for which mTOR treatment is clinically indicated (i.e. SEGA or AML).
Subjects who are, in the opinion of the investigator, unable to comply with therequirements of the study.
Study Design
Study Description
Connect with a study center
University of Alabama at Birmingham
Birmingham, Alabama 35294
United StatesActive - Recruiting
University of California at Los Angeles
Los Angeles, California 90095
United StatesActive - Recruiting
Stanford University
Palo Alto, California 94304
United StatesActive - Recruiting
Children's Hospital Colorado
Aurora, Colorado 80045
United StatesActive - Recruiting
Lurie Children's Hospital of Chicago
Chicago, Illinois 60611
United StatesActive - Recruiting
Boston Children's Hospital
Boston, Massachusetts 02115
United StatesActive - Recruiting
Washington University -- St. Louis
Saint Louis, Missouri 63110
United StatesActive - Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina 27510
United StatesActive - Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio 45229
United StatesActive - Recruiting
University of Texas HSC at Houston
Houston, Texas 77030
United StatesActive - Recruiting
Seattle Children's Hospital
Seattle, Washington 98105
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.